Brocacef NL : HUB Pharmaceutical Import Profile — Netherlands (DGFT 2022–2026)

Name: Brocacef NL : HUB Pharmaceutical Import Records from India — 13 Products, $15.5M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Brocacef NL : HUB — Pharmaceutical Importer Profile (2026) | 13 Products, $15.5M Trade | TransData Nexus

Brocacef NL : HUB

Pharmaceutical Importer · Netherlands · Diuretics Focus · $15.5M Total Trade · DGFT Verified

Brocacef NL : HUB is a pharmaceutical importer based in Netherlands with a total trade value of $15.5M across 13 products in 5 therapeutic categories. Based on 933 verified import shipments from Indian Customs (DGFT) records, Brocacef NL : HUB is the #1 buyer in 1 product including Vinorelbine. Brocacef NL : HUB sources from 1 verified Indian supplier, with Intas Pharmaceuticals Limited accounting for 100.0% of imports.

Brocacef NL : HUB — Import Portfolio & Supplier Network

Brocacef NL : HUB import network — 13 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Brocacef NL : HUB?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Intas Pharmaceuticals Limited	$6.4M	479	100.0%

Brocacef NL : HUB sources from 1 verified Indian supplier across 252 distinct formulations. The sourcing is highly concentrated — Intas Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Brocacef NL : HUB Import?

Formulation	Value	Ships
Pharma drugs & medi: sondelbay	$432.2K	11
Pharma drugs & medi: pelgraz 6MG/0.6ML	$349.5K	7
Pharma drugs & medi:sondelbay	$283.2K	7
Pharma drug&med:spironolactone	$238.9K	8
Pharma drug&med:spironolactone	$201.8K	8
Pharma drugs & medi:pelgraz 6MG/0.6ML	$183.0K	4
Pharma drug&med:tacrolimus ointme,0.1%	$173.5K	5
Pharma drug&med:cabazitaxel 20MG/ML	$150.0K	3
Pharma drug&med:tadalafil 20MG	$137.0K	3
Pharma drug&med:tadalafil 20MG	$126.3K	3
Pharma drugs & medi: carmustine 100MG/v	$123.0K	6
Pharma drug&med:exemestane 25MG 10x10t	$112.0K	3
Pharma drug&med:spironolacton	$108.2K	3
Pharma drug&med:accofil 30mu/0.5ML	$100.0K	2
Pharma drug&med:pelgraz 6MG/0.6ML pfs	$92.3K	2

Import Portfolio — Top 13 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Spironolactone	Diuretics	$5.0M	250	1.9%	6
2	Iron	Vitamins & Supplements	$4.2M	264	0.9%	12
3	Lenalidomide	Advanced Oncology	$2.0M	47	0.2%	10
4	Irinotecan	Oncology	$744.9K	66	1.8%	11
5	Exemestane	Advanced Oncology	$699.9K	20	4.8%	3
6	Vinorelbine	Advanced Oncology	$563.0K	49	14.4%	1
7	Propranolol	Cardiovascular	$441.6K	55	0.8%	8
8	Fulvestrant	Advanced Oncology	$399.3K	14	2.7%	10
9	Cytarabine	Advanced Oncology	$385.2K	42	3.6%	4
10	Cabazitaxel	Advanced Oncology	$350.0K	7	2.2%	7
11	Etoposide	Oncology	$301.3K	74	2.8%	7
12	Fludarabine	Advanced Oncology	$282.6K	20	7.3%	2
13	Topotecan	Advanced Oncology	$155.1K	25	3.0%	7

Brocacef NL : HUB imports 13 pharmaceutical products across 5 categories into Netherlands totaling $15.5M. The company is the #1 buyer for 1 product: Vinorelbine.

Brocacef NL : HUB — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Brocacef NL : HUB is a prominent pharmaceutical importer and buyer based in the Netherlands, specializing in the acquisition of finished pharmaceutical formulations from international suppliers. Operating under the Brocacef Group, the company plays a pivotal role in the Dutch pharmaceutical distribution network, ensuring the availability of a diverse range of medications to meet the needs of healthcare providers and patients across the country. The Brocacef Group, established in 1798, has a longstanding history in the healthcare sector, providing comprehensive services that encompass warehousing, logistics, and patient support programs. As part of the German PHOENIX Group, Brocacef NL : HUB benefits from a robust infrastructure and extensive experience in pharmaceutical logistics and distribution. (bitscale.ai)

2Distribution Network

Brocacef NL : HUB operates an extensive distribution network within the Netherlands, featuring strategically located warehouses and advanced logistics capabilities. The company's facilities are equipped to handle a wide array of pharmaceutical products, including temperature-sensitive medications, ensuring compliance with Good Distribution Practice (GDP) standards. This infrastructure enables Brocacef NL : HUB to efficiently supply pharmacies, hospitals, and other healthcare institutions nationwide. Additionally, the company is committed to sustainability, aiming for CO₂ neutrality by 2030, which influences its logistics and operational strategies. (brocacef.nl)

3Industry Role

In the Netherlands' pharmaceutical supply chain, Brocacef NL : HUB functions primarily as a pharmaceutical importer and wholesaler. By sourcing finished pharmaceutical formulations from international suppliers, the company ensures a steady supply of medications to the Dutch market. Its role is crucial in bridging the gap between global pharmaceutical manufacturers and local healthcare providers, facilitating the availability of a wide range of pharmaceutical products to meet diverse medical needs. This position underscores Brocacef NL : HUB's integral role in maintaining the efficiency and reliability of the Dutch pharmaceutical distribution system.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Brocacef NL : HUB

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Brocacef NL : HUB's sourcing strategy exhibits a high degree of concentration, with a significant portion of its pharmaceutical imports originating from a single supplier, Intas Pharmaceuticals Limited. This dependency indicates a strategic choice to establish a strong, long-term partnership with a reliable supplier. The substantial volume of shipments—479 in total—suggests a stable and well-coordinated relationship, likely characterized by favorable terms and consistent product quality. However, such concentration also presents potential risks, including supply chain disruptions in the event of issues with the primary supplier. To mitigate these risks, Brocacef NL : HUB may consider diversifying its supplier base or developing contingency plans to ensure continuity of supply.

2Supply Chain Resilience

Brocacef NL : HUB's supply chain resilience is closely tied to its reliance on Intas Pharmaceuticals Limited for the majority of its pharmaceutical imports. While this partnership offers stability and streamlined operations, it also exposes the company to potential vulnerabilities, such as supply disruptions or regulatory changes affecting the primary supplier. The limited diversification in its supplier base may impact the company's ability to adapt to unforeseen challenges. To enhance resilience, Brocacef NL : HUB could explore establishing relationships with additional suppliers, particularly those offering complementary product lines or alternative formulations, thereby strengthening its supply chain and reducing dependency on a single source.

Importing Pharmaceuticals into Netherlands — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for Netherlands

1Regulatory Authority & Framework

In the Netherlands, the primary regulatory authority overseeing pharmaceutical imports is the Dutch Medicines Evaluation Board (CBG). The CBG is responsible for evaluating and monitoring the safety, efficacy, and quality of medicines available in the Dutch market. Key legislation governing pharmaceutical imports includes the Medicines Act (Geneesmiddelenwet), which outlines the requirements for marketing authorization, importation, and distribution of medicinal products. For Indian generics to be marketed in the Netherlands, they must undergo a centralized procedure through the European Medicines Agency (EMA), leading to a European marketing authorization. This process ensures that all medicinal products meet the stringent standards set by the European Union for safety, efficacy, and quality.

2Import Licensing & GMP

Import licensing in the Netherlands requires that pharmaceutical products possess a valid marketing authorization issued by the CBG or the EMA. Manufacturers and importers must comply with Good Manufacturing Practice (GMP) standards, which are recognized internationally, including EU GMP, WHO GMP, and PIC/S certifications. These certifications ensure that pharmaceutical products are consistently produced and controlled according to quality standards. Additionally, wholesalers like Brocacef NL : HUB must obtain a wholesale distribution authorization, which involves demonstrating compliance with GDP guidelines to ensure the safe and effective distribution of medicinal products.

Brocacef NL : HUB — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Brocacef NL : HUB's product strategy focuses on importing finished pharmaceutical formulations across various therapeutic categories, with a particular emphasis on diuretics, advanced oncology treatments, and vitamins & supplements. The substantial import value of spironolactone, iron, lenalidomide, irinotecan, and exemestane indicates a strategic alignment with prevalent medical conditions and treatment protocols in the Netherlands. The company's portfolio concentration, with the top five products accounting for 81.5% of total imports, suggests a targeted approach to meet specific healthcare needs, potentially leading to operational efficiencies and stronger supplier relationships.

2Sourcing Profile

Brocacef NL : HUB's sourcing strategy is centered on acquiring generic pharmaceutical products from India, leveraging the country's robust manufacturing capabilities and cost advantages. The company's focus on finished formulations, rather than raw active pharmaceutical ingredients (APIs), indicates a preference for ready-to-market products that comply with European quality standards. India's established reputation in producing high-quality generics aligns with Brocacef NL : HUB's procurement objectives, facilitating a reliable and cost-effective supply chain.

3Market Positioning

Seller's Guide — How to Become a Supplier to Brocacef NL : HUB

Opportunity assessment, qualifications, and practical approach strategy

1Opportunity Assessment

There is a realistic opportunity for new Indian suppliers to engage with Brocacef NL : HUB, particularly if they can offer products that complement the company's existing portfolio or meet emerging market demands. Identifying gaps in Brocacef NL : HUB's current sourcing, such as unmet therapeutic needs or innovative formulations, could present avenues for collaboration. Establishing a relationship would require demonstrating compliance with EU regulatory standards, ensuring product quality, and aligning with Brocacef NL : HUB's operational requirements.

2Requirements & Qualifications

Indian exporters aiming to supply Brocacef NL : HUB and the broader Netherlands market must ensure that their products have valid marketing authorizations from the CBG or EMA. Compliance with EU GMP, WHO GMP, or PIC/S certifications is mandatory to meet quality standards. Additionally, adherence to labeling requirements, including Dutch language provisions, and serialization mandates is essential. Exporters should also be prepared to provide comprehensive documentation and engage in regulatory filings as required by Dutch authorities.

3How to Approach

Frequently Asked Questions — Brocacef NL : HUB

What products does Brocacef NL : HUB import from India?

Brocacef NL : HUB imports 13 pharmaceutical products across 5 categories. Top imports: Spironolactone ($5.0M), Iron ($4.2M), Lenalidomide ($2.0M), Irinotecan ($744.9K), Exemestane ($699.9K).

Who supplies pharmaceuticals to Brocacef NL : HUB from India?

Brocacef NL : HUB sources from 1 verified Indian suppliers. The primary supplier is Intas Pharmaceuticals Limited (100.0% of imports, $6.4M).

What is Brocacef NL : HUB's total pharmaceutical import value?

Brocacef NL : HUB's total pharmaceutical import value from India is $15.5M, based on 933 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Brocacef NL : HUB focus on?

Brocacef NL : HUB imports across 5 categories. The largest: Diuretics (32.3%), Advanced Oncology (30.9%), Vitamins & Supplements (27.3%).

Get Full Brocacef NL : HUB Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 3 company name variants from customs records. For current shipment-level data, contact TransData Nexus.